Recombinant VWF antibody (AA 1815-1939)

Catalog No. ABIN5646933

This Rabbit Monoclonal antibody specifically detects VWF in WB, IP, IF and IHC (p). It exhibits reactivity toward Human.

Quick Overview for Recombinant VWF antibody (AA 1815-1939) (ABIN5646933)

Target: VWF (Von Willebrand Factor (VWF))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This VWF antibody is un-conjugated

Application: Western Blotting (WB), Immunoprecipitation (IP), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: VWF-1859R

Product Details anti-VWF Antibody

Binding Specificity: AA 1815-1939

Purification: Purified

Purity: Protein A affinity chromatography

Immunogen: Amino acids 1815-1939 from the human protein were used as the immunogen for this recombinant vWF antibody.

Isotype: IgG kappa

Application Details

Application Notes: The optimal dilution of the recombinant vWF antibody for each application should be determined by the researcher.

1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 1-2 μg/mL,Immunoprecipitation: 1-2 μg/500 μg lysate,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the recombinant vWF antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Target Details for VWF

Target: VWF (Von Willebrand Factor (VWF))

Alternative Name: von Willebrand Factor / vWF

Background: Von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.